A new oral medicine for schizophrenia was approved by the US Food and Drug Administration on 27 September introducing a mechanism of action for treating the disease – a leading cause of disability worldwide. The drug, Cobenfy (xanomeline and trospium chloride), is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which is currently the standard of care. The drug was developed by Bristol-Myers Squibb Co.
